問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Nephrology

更新時間：2023-09-19

周哲毅
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周哲毅

List

8Cases

2022-03-31 - 2024-08-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2021-12-27 - 2024-07-10

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-09-21 - 2026-06-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2021-06-01 - 2021-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2018-10-01 - 2022-02-28

Phase II

Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • Condition/Disease

    Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • Test Drug

    venglustat

Participate Sites
2Sites

Recruiting2Sites

2022-04-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB